Darolutamide for treating prostate cancer

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Darolutamide 300 mg tablet in combination with androgen deprivation therapy for treating patients with:

  • high-risk non-metastatic castration-resistant prostate cancer; and

  • metastatic hormone-sensitive prostate cancer 

in view of the acceptable pricing proposal by the company and potential cost savings to the healthcare system. 

Funding status

Darolutamide 300 mg tablet is recommended for inclusion on the Medication Assistance Fund for the abovementioned indications from 1 November 2024.

Clinical indications, subsidy class and MediShield Life claim limits for darolutamide are provided in the Annex.

Darolutamide for treating prostate cancer (Published 13 Sep 24) [PDF, 114 KB]

PES Treatments for advanced prostate cancer (Updated 13 Sep 2024) [PDF, 72 KB]